Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001133796-17-000103
Filing Date
2017-07-21
Accepted
2017-07-21 16:29:02
Documents
7
Period of Report
2017-08-18
Effectiveness Date
2017-07-21

Document Format Files

Seq Description Document Type Size
1 DEF 14A k471067_17478-def14a.htm DEF 14A 415713
2 GRAPHIC line.gif GRAPHIC 43
3 GRAPHIC logo_myovant.jpg GRAPHIC 44615
4 GRAPHIC sig_lynn-seely.jpg GRAPHIC 20370
5 GRAPHIC spacer.gif GRAPHIC 43
6 GRAPHIC k471067_pc1.jpg GRAPHIC 381521
7 GRAPHIC k471067_pc2.jpg GRAPHIC 835944
  Complete submission text file 0001133796-17-000103.txt   2183424
Mailing Address 20-22 BEDFORD ROW LONDON X0 WC1R 4JS
Business Address 20-22 BEDFORD ROW LONDON X0 WC1R 4JS (441) 824-8101
Myovant Sciences Ltd. (Filer) CIK: 0001679082 (see all company filings)

EIN.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: DEF 14A | Act: 34 | File No.: 001-37929 | Film No.: 17976835
SIC: 2834 Pharmaceutical Preparations